The Effect of Protein Kinase C Activation on Gz-Mediated Regulation of Type 2 and 6 Adenylyl CyclasesHo M.K.C. · Chan J.S.C. · Yung L.Y. · Wong Y.H.
Department of Biology and Biotechnology Research Institute, Hong Kong University of Science and Technology, Hong Kong, China
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Three serine-to-alanine mutants of the α subunit of the heterotrimeric G protein Gz (αz) were examined for their signaling properties in the presence of phorbol ester treatment. All three αz mutants resembled wild-type αz in their abilities to inhibit αs-stimulated type 6 adenylyl cyclase (AC6) and phorbol ester treatment reduced their magnitudes of inhibition. Depending on the permissive condition, the βγ-mediated stimulation of type 2 adenylyl cyclase (AC2) was differentially regulated by αz and the three mutants. Mutation of Ser27 but not Ser16 of αz affected the efficient release of βγ subunits upon receptor activation and abolished the stimulation of phosphorylated but not αs-stimulated AC2.
© 2000 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.